Aptose Biosciences Inc. (APTOF)
OTCMKTS
· Delayed Price · Currency is USD
0.8500
-0.0600 (-6.59%)
Jun 24, 2025, 4:00 PM EDT
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,641,000
Market Cap
2.20M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
American Oncology Network | 1,914 |
CytoDyn | 9 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Aptose Biosciences News
- 4 days ago - Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML - GlobeNewsWire
- 7 days ago - Aptose Provides Corporate Updates - GlobeNewsWire
- 12 days ago - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - GlobeNewsWire
- 4 weeks ago - Aptose Announces Results from Annual and Special Meeting of Shareholders - GlobeNewsWire
- 5 weeks ago - Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - GlobeNewsWire
- 5 weeks ago - Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - GlobeNewsWire
- 2 months ago - Aptose Announces Auditor Not Standing for Re-Appointment - GlobeNewsWire
- 2 months ago - Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire